Evidence map›Paper›PMID 24658303›Full record

ArticleDiabetes2014

Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin's metabolic action in the presence of insulin resistance.

Weidong Chai, Xingxing Zhang, Eugene J Barrett, Zhenqi Liu

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04133922 early_phase1withdrawnstarted 2019, after this paper: background citation

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Ran2019Enrolled0Registered outcomes5Posted comparisons0ConditionsInsulin Sensitivity/Resistance, Type 1 DiabetesArmsDextrose 20 % in Water, GLP-1, Insulin
PMID 27295427PMID 27436611PMID 28479155PMID 15983263PMID 16567818PMID 17711996PMID 18612041PMID 1874938PMID 20739685PMID 21610226PMID 2189893PMID 23657563other papers from this trial
Open the trial in the graph
NCT03520569 early_phase1completednot on this mapstarted 2019, after this paper: background citation

Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults

TypeinterventionalSponsorUniversity of VirginiaRan2019 to 2021Enrolled15ConditionsVascular Stiffness, Insulin SensitivityArmsOctreotide, Insulin, Dextrose 20% solution
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Incretins in the Therapy of Diabetic Kidney Disease.International journal of molecular sciences · 2021
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Weidong ChaiDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA.
Xingxing ZhangDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VADepartment of Pediatrics, Central South University 2nd Xiangya Hospital, Hunan, China.
Eugene J BarrettDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA.
Zhenqi LiuDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA zl3e@virginia.edu.
University of Virginia Health System · US

Funding

NHLBI NIH HHS R01 HL094722NHLBI NIH HHS R01-HL-094722
6 · The paper itself

Abstract

Glucagon-like peptide 1 (GLP-1) acutely recruits muscle microvasculature, increases muscle delivery of insulin, and enhances muscle use of glucose, independent of its effect on insulin secretion. To examine whether GLP-1 modulates muscle microvascular and metabolic insulin responses in the setting of insulin resistance, we assessed muscle microvascular blood volume (MBV), flow velocity, and blood flow in control insulin-sensitive rats and rats made insulin-resistant acutely (systemic lipid infusion) or chronically (high-fat diet [HFD]) before and after a euglycemic-hyperinsulinemic clamp (3 mU/kg/min) with or without superimposed systemic GLP-1 infusion. Insulin significantly recruited muscle microvasculature and addition of GLP-1 further expanded muscle MBV and increased insulin-mediated glucose disposal. GLP-1 infusion potently recruited muscle microvasculature in the presence of either acute or chronic insulin resistance by increasing muscle MBV. This was associated with an increased muscle delivery of insulin and muscle interstitial oxygen saturation. Muscle insulin sensitivity was completely restored in the presence of systemic lipid infusion and significantly improved in rats fed an HFD. We conclude that GLP-1 infusion potently expands muscle microvascular surface area and improves insulin's metabolic action in the insulin-resistant states. This may contribute to improved glycemic control seen in diabetic patients receiving incretin-based therapy.

Indexed as

Insulin ResistanceAnimalsDiet, High-FatGlucagon-Like Peptide 1GlucoseInsulinLipidsMaleMuscle, SkeletalNeovascularization, PhysiologicRatsRats, Sprague-DawleyGlucagon-Like Peptide 1GlucoseInsulinLipids

Identifiers

PMID24658303
PMCPMC4113068
OpenAlexW2129639460

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.